214 related articles for article (PubMed ID: 37662962)
21. Anti-PD-1 antibody monotherapy versus anti-PD-1 plus anti-CTLA-4 combination therapy as first-line immunotherapy in unresectable or metastatic mucosal melanoma: a retrospective, multicenter study of 329 Japanese cases (JMAC study).
Nakamura Y; Namikawa K; Yoshikawa S; Kiniwa Y; Maekawa T; Yamasaki O; Isei T; Matsushita S; Nomura M; Nakai Y; Fukushima S; Saito S; Takenouchi T; Tanaka R; Kato H; Otsuka A; Matsuya T; Baba N; Nagase K; Inozume T; Fujimoto N; Kuwatsuka Y; Onishi M; Kaneko T; Onuma T; Umeda Y; Ogata D; Takahashi A; Otsuka M; Teramoto Y; Yamazaki N
ESMO Open; 2021 Dec; 6(6):100325. PubMed ID: 34839104
[TBL] [Abstract][Full Text] [Related]
22. Two Pyroptosis-Related Subtypes with Distinct Immune Microenvironment Characteristics and a Novel Signature for Predicting Immunotherapy Response and Prognosis in Uveal Melanoma.
Lei S; Li H
Curr Eye Res; 2022 Jun; 47(6):930-943. PubMed ID: 35348009
[TBL] [Abstract][Full Text] [Related]
23. The immune checkpoint VISTA exhibits high expression levels in human gliomas and associates with a poor prognosis.
Ghouzlani A; Lakhdar A; Rafii S; Karkouri M; Badou A
Sci Rep; 2021 Nov; 11(1):21504. PubMed ID: 34728682
[TBL] [Abstract][Full Text] [Related]
24. Immune Checkpoint Protein Expression Defines the Prognosis of Advanced Thyroid Carcinoma.
Luo Y; Yang YC; Shen CK; Ma B; Xu WB; Wang QF; Zhang Y; Liao T; Wei WJ; Wang Y
Front Endocrinol (Lausanne); 2022; 13():859013. PubMed ID: 35574031
[TBL] [Abstract][Full Text] [Related]
25. Comprehensive analysis of cutaneous and uveal melanoma liver metastases.
Hoefsmit EP; Rozeman EA; Van TM; Dimitriadis P; Krijgsman O; Conway JW; Pires da Silva I; van der Wal JE; Ketelaars SLC; Bresser K; Broeks A; Kerkhoven RM; Reeves JW; Warren S; Kvistborg P; Scolyer RA; Kapiteijn EW; Peeper DS; Long GV; Schumacher TNM; Blank CU
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33262254
[TBL] [Abstract][Full Text] [Related]
26. Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.
Blando J; Sharma A; Higa MG; Zhao H; Vence L; Yadav SS; Kim J; Sepulveda AM; Sharp M; Maitra A; Wargo J; Tetzlaff M; Broaddus R; Katz MHG; Varadhachary GR; Overman M; Wang H; Yee C; Bernatchez C; Iacobuzio-Donahue C; Basu S; Allison JP; Sharma P
Proc Natl Acad Sci U S A; 2019 Jan; 116(5):1692-1697. PubMed ID: 30635425
[TBL] [Abstract][Full Text] [Related]
27. Immune functions as a ligand or a receptor, cancer prognosis potential, clinical implication of VISTA in cancer immunotherapy.
Im E; Sim DY; Lee HJ; Park JE; Park WY; Ko S; Kim B; Shim BS; Kim SH
Semin Cancer Biol; 2022 Nov; 86(Pt 2):1066-1075. PubMed ID: 34428551
[TBL] [Abstract][Full Text] [Related]
28. Immunotherapy for the Treatment of Uveal Melanoma: Current Status and Emerging Therapies.
Komatsubara KM; Carvajal RD
Curr Oncol Rep; 2017 Jul; 19(7):45. PubMed ID: 28508938
[TBL] [Abstract][Full Text] [Related]
29. The prognostic landscape of adaptive immune resistance signatures and infiltrating immune cells in the tumor microenvironment of uveal melanoma.
Wang Y; Xu Y; Dai X; Lin X; Shan Y; Ye J
Exp Eye Res; 2020 Jul; 196():108069. PubMed ID: 32439398
[TBL] [Abstract][Full Text] [Related]
30. Role of immune checkpoint inhibitors and novel immunotherapies in uveal melanoma.
Jindal V
Chin Clin Oncol; 2018 Feb; 7(1):8. PubMed ID: 29486567
[TBL] [Abstract][Full Text] [Related]
31. PRAME as a Potential Target for Immunotherapy in Metastatic Uveal Melanoma.
Gezgin G; Luk SJ; Cao J; Dogrusöz M; van der Steen DM; Hagedoorn RS; Krijgsman D; van der Velden PA; Field MG; Luyten GPM; Szuhai K; Harbour JW; Jordanova ES; Heemskerk MHM; Jager MJ
JAMA Ophthalmol; 2017 Jun; 135(6):541-549. PubMed ID: 28448663
[TBL] [Abstract][Full Text] [Related]
32. Analysis of the immune checkpoint V-domain Ig-containing suppressor of T-cell activation (VISTA) in endometrial cancer.
Zong L; Mo S; Sun Z; Lu Z; Yu S; Chen J; Xiang Y
Mod Pathol; 2022 Feb; 35(2):266-273. PubMed ID: 34493823
[TBL] [Abstract][Full Text] [Related]
33. MIR155HG is a prognostic biomarker and associated with immune infiltration and immune checkpoint molecules expression in multiple cancers.
Peng L; Chen Z; Chen Y; Wang X; Tang N
Cancer Med; 2019 Dec; 8(17):7161-7173. PubMed ID: 31568700
[TBL] [Abstract][Full Text] [Related]
34. FOXD3 Regulates VISTA Expression in Melanoma.
Rosenbaum SR; Knecht M; Mollaee M; Zhong Z; Erkes DA; McCue PA; Chervoneva I; Berger AC; Lo JA; Fisher DE; Gershenwald JE; Davies MA; Purwin TJ; Aplin AE
Cell Rep; 2020 Jan; 30(2):510-524.e6. PubMed ID: 31940493
[TBL] [Abstract][Full Text] [Related]
35. Novel immune checkpoint targets: moving beyond PD-1 and CTLA-4.
Qin S; Xu L; Yi M; Yu S; Wu K; Luo S
Mol Cancer; 2019 Nov; 18(1):155. PubMed ID: 31690319
[TBL] [Abstract][Full Text] [Related]
36. VISTA, PDL-L1, and
Tinca AC; Cocuz IG; Șincu MC; Niculescu R; Sabău AH; Chiorean DM; Szőke AR; Cotoi OS
Medicina (Kaunas); 2022 Jan; 58(1):. PubMed ID: 35056382
[TBL] [Abstract][Full Text] [Related]
37. Circulating immune profile can predict survival of metastatic uveal melanoma patients: results of an exploratory study.
Rossi E; Zizzari IG; Di Filippo A; Acampora A; Pagliara MM; Sammarco MG; Simmaco M; Lionetto L; Botticelli A; Bria E; Marchetti P; Blasi MA; Tortora G; Schinzari G; Nuti M
Hum Vaccin Immunother; 2022 May; 18(3):2034377. PubMed ID: 35258435
[TBL] [Abstract][Full Text] [Related]
38. Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway.
Zheng S; Zhang K; Zhang X; Xiao Y; Wang T; Jiang S
J Med Chem; 2022 Sep; 65(18):11900-11912. PubMed ID: 36083840
[TBL] [Abstract][Full Text] [Related]
39. VISTA expression and patient selection for immune-based anticancer therapy.
Martin AS; Molloy M; Ugolkov A; von Roemeling RW; Noelle RJ; Lewis LD; Johnson M; Radvanyi L; Martell RE
Front Immunol; 2023; 14():1086102. PubMed ID: 36891296
[TBL] [Abstract][Full Text] [Related]
40. Negative immune checkpoint regulation by VISTA: a mechanism of acquired resistance to anti-PD-1 therapy in metastatic melanoma patients.
Kakavand H; Jackett LA; Menzies AM; Gide TN; Carlino MS; Saw RPM; Thompson JF; Wilmott JS; Long GV; Scolyer RA
Mod Pathol; 2017 Dec; 30(12):1666-1676. PubMed ID: 28776578
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
